TELO Q2 2025 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$5M

Net Income

-$5M

EPS (Diluted)

$-0.17

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$696,444

Free Cash Flow

-$696,440

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$829,611

Total Liabilities

$348,388

Stockholders' Equity

$481,223

Cash & Equivalents

$754,323

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$5M	-$1M	-243.8%
Net Income	-$5M	-$1M	-249.9%